Covetrus Announces CEO and Chairman Transition

Benjamin Shaw steps down as CEO and president and will serve as a strategic advisor to the board of Covetrus. Board chair Wolin to assume role as acting CEO and president, lead independent director Laskawy to serve as board chair.

PORTLAND, MaineOctober 22, 2019 – Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, today announced that Benjamin Shaw has stepped down as the company’s president and chief executive officer and will transition to a strategic advisor to the board. Benjamin Wolin, who currently serves as the company’s chair of the board, will assume the role of acting CEO and president. Philip A. Laskawy, the board’s lead independent director, will take over as board chair. Read more

Related Posts

Bar Harbor approves Jackson Lab’s $33M expansion for rare disease research

The Bar Harbor Planning Board has approved a plan by the Jackson Laboratory to build a 20,000-square-foot expansion to its Rare Disease Translational...

22 August 2024

Bigelow lab receives $7 million for algae research, business development

Researchers at Bigelow Laboratory for Ocean Sciences believe algae can make a big splash in the agricultural, aquaculture and pharmaceutical industries,...

21 August 2024

Should Maine create a public medical school? UMaine System will study the question

The University of Maine System said this week it will work with a national consultant to study the feasibility of launching the state’s...

21 August 2024